Real-World PH1 study tracks lumasiran safety and disease progression
NCT ID NCT04982393
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study follows 207 people diagnosed with primary hyperoxaluria type 1 (PH1) to understand how the disease naturally progresses over time. It also tracks the long-term safety and real-world effectiveness of the drug lumasiran. The goal is to gather information that can help doctors better manage PH1 in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPEROXALURIA TYPE 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Trial Site
Phoenix, Arizona, 85016, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20010, United States
-
Clinical Trial Site
Boston, Massachusetts, 02115, United States
-
Clinical Trial Site
Rochester, Minnesota, 55905, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45229, United States
-
Clinical Trial Site
Pittsburgh, Pennsylvania, 15213, United States
-
Clinical Trial Site
Dallas, Texas, 75390, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Ghent, Belgium
-
Clinical Trial Site
Liège, Belgium
-
Clinical Trial Site
Hamilton, Ontario, Canada
-
Clinical Trial Site
Toronto, Ontario, Canada
-
Clinical Trial Site
Laurier, Quebec, Canada
-
Clinical Trial Site
Bordeaux, France
-
Clinical Trial Site
Lyon, France
-
Clinical Trial Site
Paris, France
-
Clinical Trial Site
Berlin, Germany
-
Clinical Trial Site
Cologne, Germany
-
Clinical Trial Site
Hamburg, Germany
-
Clinical Trial Site
Jerusalem, Israel
-
Clinical Trial Site
Orbassano, Torino, Italy
-
Clinical Trial Site
Milan, Italy
-
Clinical Trial Site
Verona, Italy
-
Clinical Trial Site
Amsterdam, Netherlands
-
Clinical Trial Site
Santa Cruz de Tenerife, Canary Islands, Spain
-
Clinical Trial Site
Barcelona, Spain
-
Clinical Trial Site
Las Palmas, Spain
-
Clinical Trial Site
Bern, Switzerland
-
Clinical Trial Site
London, England, United Kingdom
-
Clinical Trial Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.